Test medicine add-on to erlotinib for EGFR lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial tests whether adding OBI-833/OBI-821 to the standard targeted pill erlotinib works better for some people with EGFR-mutated lung cancer. It may help shrink tumors that already started responding to erlotinib.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 20 years old.
- You have non-small cell lung cancer that is stage IIIB, IIIC, IVA, or IVB.
- Your tumor has an EGFR exon 19 deletion or exon 21 L858R mutation (confirmed by testing).
- Your tumor is Globo H positive (Globo H H-score at least 100 on a central lab test).
- You have been on erlotinib 150 mg/day for about 3 months (±1 month), and your cancer is stable or shrinking (SD or PR). You must be able to stay on the same erlotinib dose.
- You have at least one measurable tumor spot on scans, your general strength is ECOG 0–1, and your bloodwork/liver/kidney tests meet the study limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
This trial tests combining a targeted pill (EGFR-TKI) with an antibody drug (bevacizumab) for people with advanced non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if this combination works better than the pill alone as a first treatment.
This trial compares two targeted therapy pills, aumolertinib and osimertinib, for people with a specific EGFR mutation in advanced non-small-cell lung cancer that has spread. Both drugs are designed to block cancer growth signals. The study aims to see which one works better as a first treatment.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests an investigational drug called EDB-102 for people with a specific type of advanced lung cancer (non-small cell lung cancer) that has spread to the liver. It is for patients whose cancer has stopped responding to a certain targeted therapy (like osimertinib). The study will check the safety of the drug and see if it helps shrink tumors.
This trial tests whether removing the main lung tumor with surgery and then taking the targeted drug osimertinib helps people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this approach can improve outcomes compared to just taking the drug alone.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.